The #FDA released a statement today ALERTING laboratory personnel and healthcare providers about #Illumina cybersecurity vulnerabilities. Illumina supplies the majority of genomic laboratories with instrumentation to sequence DNA. The letter to healthcare providers discusses that a user may operate the technology for both clinical diagnostic use or research purposes. Ultimately the following is the most important information presented:
The cybersecurity vulnerability affects the Local Run Manager (LRM) software. An unauthorized user could exploit the vulnerability by:
- taking control of the instrument remotely;
- operating the system to alter settings, configurations, software, or data on the instrument or a customer’s network; or
- impacting patient test results in the instruments intended for clinical diagnosis, including causing the instruments to provide no results or incorrect results, altered results, or a potential data breach.
#CenterForGenomicInterpretation appreciates the #FDA staying on top of cybersecurity events that could impact patient test results.
Labs should contact Illumina, if they didn’t receive a notification for a temporary patch until a permanent fix is found. email@example.com